Table. Clinical characteristics of patients infected with Mycobacterium kyorinense and antimicrobial susceptibility of the organism*.
| Characteristic |
Patient/strain no. |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1† |
2‡ |
3‡ |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11§ |
|
| Year of diagnosis | 2005 | 2006 | 2008 | 2008 | 2009 | 2009 | 2010 | 2010 | 2011 | 2011 | 2007 |
| Age, y | 89 | 64 | 70 | 81 | 50 | 67 | 72 | 48 | 66 | 60 | 26 |
| Sex | M | F | M | M | M | M | M | F | M | M | M |
| Major infection site | Lung | Lung | Lung | Lung | Lymph node | Lung | Lung | Joint | Lung | Lung | Lung |
| Specimen | Sputum | Sputum | Sputum | BAL | Pus | BAL | Sputum | Pus | Sputum | Sputum | Sputum |
| Coexisting disease | COPD | Breast cancer | None | None | MDS | None | None | RA, SLE | None | COPD | NA |
| Country |
Japan |
Japan |
Japan |
Japan |
Japan |
Japan |
Japan |
Japan |
Japan |
Japan |
Brazil |
| AM drug MIC, μg/mL | |||||||||||
| STR | 0.25 | 0.25 | 0.25 | S | ND | 0.25 | 0.125 | 0.5 | 0.25 | 0.5 | S |
| EMB | 4 | 4 | 2 | R | 128 | 2 | 1 | 2 | 4 | 4 | S |
| KAN | 0.5 | 1 | 0.25 | S | ND | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | ND |
| INH | 16 | 16 | 32 | R | 2 | 0.5 | 8 | 4 | 1 | 4 | R |
| RIF | 32 | 32 | 32 | R | 32 | 32 | 32 | 32 | 32 | 32 | R |
| LVX | 0.125 | 0.125 | 0.03 | R | 0.25 | 0.06 | 0.06 | 0.125 | 0.125 | 0.25 | ND |
| CLR | 0.03 | 0.03 | 0.03 | ND | 0.03 | 0.03 | ND | ND | 0.03 | 0.125 | ND |
| AMK |
0.5 |
0.5 |
0.5 |
ND |
0.5 |
1 |
ND |
0.5 |
0.5 |
0.5 |
S |
| Clinical efficacy of AM drug combination | |||||||||||
| Efficacious | None | None | None | None | CLR, RIF, LVX, AMK | CLR, STR, MXF | None | LVX, EMB, CLR | RIF, CLR, LVX | CLR, LVX | NA |
| Nonefficacious | BIP | None | RFB, EMB, CLR | INH, EMB, RIF | None | RIF, EMB, CLR, RIF, AZM, LVX | CLR, RIF, EMB | INH, RIF, EMB | INH, RIF, EMB | RFB, EMB | NA |
| Outcome | Dead | Dead | Dead | Dead | Alive | Alive | Alive | Alive | Alive | Alive | Dead |
*BAL, bronchoalveolar lavage; COPD, chronic obstructive pulmonary disease; MDS, myelodysplastic syndrome; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; NA, not available; AM, antimicrobial; STR, streptomycin; S, sensitive; ND, not done; EMB, ethambutol; R, resistant; KAN, kanamycin; INH, isoniazid; RIF, rifampin; LVX, levofloxacin; CLR, clarithromycin; AMK, amikacin; AM, antimicrobial; RFB, rifabutin; MXF, moxifloxacin; BIP, biapenem; AZM, azithromycin. †Reported in (1,2). ‡Reported in (1). §Reported in (3). ¶Strains 1–10 (except for 4): assayed by broth microdilution MIC for nontuberculosis mycobacteria (BrothMIC NTM; Kyokuto Pharmaceutical Industrial Co., Ltd., Tokyo, Japan). Strains 4 and 11: susceptibility test performed by using Vite Spectrum SR (Kyokuto Pharmaceutical Industrial Co., Ltd.) and BACTEC MGIT 960 Mycobacterial Detection System (Becton, Dickinson and Company, Franklin Lakes, NJ, USA), respectively; therefore, numeric MIC data were not available for these strains.